apposters.com
GelMEDIX, Inc.
Edit

GelMEDIX, Inc.

https://www.gelmedix.com/
Last activity: 23.02.2026
Active
Categories: BiotechCellTherapyHealthcareHydrogelRegenerativeMedicineTherapiesVision
GelMEDIX is a biotechnology company developing regenerative medicines committed to combatting vision loss with our groundbreaking biomaterials platform. ​Our lead program is focused on preserving vision for patients suffering from Geographic Atrophy (GA), the leading cause of blindness in adults over 60. With no approved therapies to maintain vision, patients continue to lose their independence. Regenerative medicine, specifically retinal pigment epithelial (RPE) cell therapy, has the potential to transform care by regenerating lost retina and preserving vital structures required for vision. ​Our iPSC-derived RPE cell therapy utilizes an advanced hydrogel scaffold, demonstrating remarkable visual preservation for up to 92 days in preclinical studies, all while eliminating the risks that have plagued previous therapies. Join us on this exciting journey toward restoring sight!
Mentions
4
Location: United States
Total raised: $13M

Funding Rounds 1

DateSeriesAmountInvestors
17.02.2026Seed$13MBeacon Ang...

Mentions in press and media 4

DateTitleDescription
23.02.2026GelMEDIX Secures $13 Million to Advance Vision RestorationGelMEDIX, a biotechnology innovator, closed a $13 million seed funding round. Safar Partners spearheaded the investment. This capital fuels the company's lead program, GMX-101. GMX-101 targets late-stage Geographic Atrophy, a devastating fo...
17.02.2026GelMEDIX Raises $13M in Seed FundingGelMEDIX, a Cambridge, MA-based biotechnology company developing regenerative therapies to restore vision, raised $13M in Seed funding. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Bosto...
17.02.2026GelMEDIX: $13 Million Seed Funding Closed For Vision Restoration Biotechnology PlatformGelMEDIX, a biotechnology company developing regenerative therapies to restore vision, has completed a $13 million seed financing round led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Bost...
-GelMEDIX“Home | GelMEDIX, Inc.”

Reviews 0

Sign up to leave a review

Sign up Log In